The developments of molecular targeted therapy for non-GIST soft tissue sarcomas (STSs) lagged behind those for GISTs by about 10 years; the main reasons for this lag are the diversity of the heterogeneity of STSs and the lack of driver mutations such as c-kit in GISTs. Here, KIT is linked to gastrointestinal stromal tumor.